No Data
DiaMedica Therapeutics Upcoming Conference Participation
Oppenheimer Reiterates Outperform on DiaMedica Therapeutics, Maintains $6 Price Target
DiaMedica Therapeutics Analyst Ratings
Earnings Call Summary | DiaMedica Therapeutics(DMAC.US) Q2 2024 Earnings Conference
Express News | DiaMedica Reiterates Its Guidance That Full Enrollment For The 144 Patients For The Interim Analysis Will Be Completed In The First Quarter Of 2025
DiaMedica Therapeutics | 10-Q: Q2 2024 Earnings Report